3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Hyperglycemia
1
Breast Neoplasms
1
Interventions
pembrolizumab
1270
Specimen Handling
870
Carboplatin
831
Magnetic Resonance Spectroscopy
808
Cyclophosphamide
802
Cisplatin
728
Nivolumab
658
Paclitaxel
631
Radiotherapy
573
Gemcitabine
572
Biopsy
529
Bevacizumab
475
Dexamethasone
440
fludarabine
407
Docetaxel
378
venetoclax
370
Oxaliplatin
365
Capecitabine
356
Fluorouracil
354
atezolizumab
341
durvalumab
334
Rituximab
332
Doxorubicin
316
Radiosurgery
309
Pemetrexed
305
Drug Therapy
302
Ipilimumab
294
Standard of Care
293
Etoposide
285
Radiation
279
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Vildagliptin
×
1 year
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled